Name: Recombinant Human Anti-CD33 x Human Anti-CD64 Bispecific Antibody (scIgG)
SKU: SCIGG-H291
Rating: 5 (1 reviews)

Recombinant Anti-CD33 x Anti-CD64 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD33 and anti-CD64 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD33 & CD64

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer

Targets

Target 1

CD33

Gene ID

945

UniProt ID

P20138

Alternative Names

CD33; CD33 molecule; Cluster of differentiation 33; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD33 x Human Anti-CD64 Bispecific Antibody (scIgG) (SCIGG-H291). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD33 x Human Anti-CD64 Bispecific Antibody (scIgG) (CAT#: SCIGG-H291)

Specifications

Targets

Customer Reviews and Q&As